Carcinoma, Lung Neoplasms, Non-small-cell Lung Cancer
Conditions
Keywords
Circulating Tumor DNA, Half time, Lung cancer, Surgery, Surveillance
Brief summary
Previous study showed circulating tumor DNA levels reflect the total systemic tumor burden. Circulating tumor DNA levels should decrease after complete surgery and could be increase as tumor recurrence. Few study investigated the half time of circulating tumor DNA in lung cancer patients that no criterion has been established of how to use it for surveillance.
Detailed description
For lung cancer patients who received surgery, multiple time of plasma will be collected before or after surgery. A series of mutations will be detected in plasma before surgery based on next generation sequencing. The positive mutation will be traced after surgery and in follow up.
Interventions
None listed
Sponsors
National Natural Science Foundation of China
Peking University People's Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Suspected lung cancer before surgery * No malignant tumor history within the past 5 years * The pulmonary nodule is not pure ground glass opacity * Patients must have given written informed consent
Exclusion criteria
* Multiple primary lung cancer * R1,R2 resection * Histology confirmed not non-small cell lung cancer * Unqualified blood samples
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Half-life of circulating tumor DNA after surgery | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| The variation of circulating tumor DNA level before and after surgery | 3 months |
| Correlation of circulating tumor DNA level after surgery with tumor recurrence | 3 years |
| Correlation of circulating tumor DNA level after surgery with clinical features | 3 months |
Countries
China
Outcome results
None listed